Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.53 |
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1220844 | 0.88 | L3MBTL1 (0.53) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1221320 | 0.88 | CYP19A1 (0.55) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1219453 | 0.86 | CYP19A1 (0.52) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL27594200 | 0.85 | NOTUM (0.60) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1221306 | 0.84 | MAPT (0.66) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1221909 | 0.84 | L3MBTL1 (0.59) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3717490 | 0.83 | L3MBTL1 (0.54) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1221249 | 0.82 | CXCR1 (0.58) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL9219309 | 0.81 | MAPT (0.51) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1221372 | 0.81 | RAB9A (0.51) | MAPTL3MBTL1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101538267-B | Imidazo [4,5-c ] pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV | 2015-04-29 | — | — | CN | disclosed |
| EP-2546254-A1 | Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2013-01-16 | — | — | EP | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-1706403-B9 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | LEUVEN K U RES & DEV (BE) | 2012-07-25 | — | — | EP | disclosed |
| EP-1706403-B1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | LEUVEN K U RES & DEV (BE) | 2012-02-08 | — | — | EP | disclosed |
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| WO-2010081145-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2178877-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GlaxoSmithKline LLC (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2161273-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2010-03-10 | — | — | EP | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| WO-2010006096-A1 | PROCESSES FOR THE PREPARATION OF ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
| CN-101538267-A | Imidazo [4, 5-c ] pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV GILEAD SC (BE) | 2009-09-23 | — | — | CN | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC | 2009-03-19 | — | — | US | disclosed |
| WO-2009011787-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| CN-1902198-A | Imidazo [4, 5-c ] pyridine compounds and methods of antiviral treatment | K U LEUVEN RES & DEV GERHARD P (BE) | 2007-01-24 | — | — | CN | disclosed |
| EP-1706403-A2 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U.Leuven Research & Development (BE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005063744-A2 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | HAVCR2, SARS1, RPL35 | MAPT 1426/4885L3MBTL1 3512/4885SMN1; SMN2 495/4885 |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | CYP3A5, TPMT, ZC3HAV1 | MAPT 4389/4885L3MBTL1 3379/4885SMN1; SMN2 2150/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | MAPT 4159/4885L3MBTL1 3243/4885SMN1; SMN2 2893/4885 |
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, RPL35 | MAPT 1426/4885L3MBTL1 3512/4885SMN1; SMN2 495/4885 |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HAVCR2, SARS1, RPL35 | MAPT 1426/4885L3MBTL1 3512/4885SMN1; SMN2 495/4885 |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | CYP3A5, TPMT, TYMP | MAPT 4436/4885L3MBTL1 3532/4885SMN1; SMN2 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.